RxDoctor Payments Data

Sudhir Aggarwal

Neurology · Paoli, PANPI 1588942643

Payments from drug & device makers

$75,289in general payments, 2019–2025

Across 634 payments — averaging $118.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$39K
  • Janssen Research & Development, LLC$26K
  • Biogen$957
  • UCB, Inc.$516
  • Novartis$495
  • Pfizer$489
  • plus $7K from 54 others

What the payments were for

  • Consulting fees$3001%
  • Speaking & faculty fees$37,36276%
  • Travel & lodging$6321%
  • Food & beverage$10,54222%
  • Education$280%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)135$39,355
Janssen Research & Development, LLC2$26,425
Biogen41$957
UCB, Inc.41$516
Novartis29$495
Pfizer35$489
Biohaven Pharmaceutical Holding Company Ltd.4$473
Teva Pharmaceuticals USA, Inc.23$395
Sunovion Pharmaceuticals Inc.29$389
Amgen14$329
AstraZeneca(2 entities)17$323
Genentech USA, Inc.15$298
Lilly USA, LLC13$254
Lundbeck LLC13$241
Argenx US, Inc.11$239
Neurocrine Biosciences, Inc.12$238
Acadia Pharmaceuticals Inc18$238
Sanofi13$234
Amneal Pharmaceuticals LLC11$202
Medtronic1$201
Biohaven Pharmaceuticals, Inc.13$179
Merz Pharmaceuticals, LLC8$149
Boston Scientific6$133
Portola Pharmaceuticals, LLC7$129
Takeda Pharmaceuticals U.S.A., Inc.6$128
Adamas Pharmaceuticals, Inc.7$127
SK Life Science, Inc.6$125
Abbott5$118
MDD US Operations, LLC6$109
Eisai Inc.5$108
Johnson & Johnson(2 entities)6$107
Avanir Pharmaceuticals, Inc.6$104
Tanabe Pharma America, Inc.4$84
Acorda Therapeutics, Inc4$82
EMD Serono, Inc.4$75
GE HealthCare3$73
Sumitomo Pharma America, Inc.5$73
Neurelis, Inc.4$73
Axsome Therapeutics, Inc.3$67
CSL Behring4$65
Sanofi-aventis U.S. LLC2$59
Otsuka America Pharmaceutical, Inc.3$53
Merz North America, Inc.3$52
Kyowa Kirin, Inc.2$49
Exact Sciences2$48
GSK2$48
Grifols USA, LLC2$47
TG Therapeutics, Inc.2$40
Bristol Myers Squibb2$40
Regeneron Healthcare Solutions, Inc.2$39
Philips North America LLC1$36
Gilead1$27
Corium, LLC1$27
Zyla Life Sciences, Inc.2$26
Greenwich Biosciences, Inc.1$24
Idorsia Pharmaceuticals US Inc1$23
Upsher-smith Laboratories LLC1$23
Catalyst Pharmaceuticals, Inc.1$20
Appliedvr Inc1$20
Averitas Pharma Inc.1$19

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$75,289 in reported general payments places this provider in the 85th percentile of 941 neurology providers in Pennsylvania.

See all neurology providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$963,175
Medicare patients
321
Services billed
58,258

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OctagamImmun Globg(Igg)/Malt/Iga Ov5073$1,603,320
Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov5053$1,037,244
Gamunex-CImmune Globul G/Gly/Iga Avg 4661$711,629
PanzygaImmun Glob G(Igg)-Ifas/Glycine54$708,031
PrivigenImmun Glob G(Igg)/Pro/Iga 0-5029$637,085
GammakedImmune Globul G/Gly/Iga Avg 4615$467,337
IngrezzaValbenazine Tosylate12$102,549
UbrelvyUbrogepant45$83,348
Nurtec OdtRimegepant Sulfate23$79,186
RytaryCarbidopa/Levodopa18$40,453
AptiomEslicarbazepine Acetate19$39,847
Aimovig AutoinjectorErenumab-Aooe24$32,463
Carbidopa-LevodopaCarbidopa/Levodopa113$4,820
Lacosamide27$3,853
Rasagiline Mesylate13$2,942

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerOctagam, Panzyga, Nurtec Odt$489$2,390,536150 claims
Takeda Pharmaceuticals U.S.A., Inc.Gammagard Liquid$128$1,037,24453 claims
Grifols USA, LLCGamunex-C$47$711,62961 claims
CSL BehringPrivigen$65$637,08529 claims
Neurocrine Biosciences, Inc.Ingrezza$238$102,54912 claims
AbbVieUbrelvy$39,355$83,34845 claims
Amneal Pharmaceuticals LLCRytary$202$40,45318 claims
Sunovion Pharmaceuticals Inc.Aptiom$389$39,84719 claims
Upsher-smith Laboratories LLCTopiramate$23$74137 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 941 neurology providers in Pennsylvania.

Other neurology in Paoli

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →